Objective: This study investigates the clinical and demographic characteristics of girlsdiagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periodsto assess potential changes during the COVID-19 pandemic.
Methods: A retrospective cohort study was conducted on patients admitted to the Pediatric
Endocrinology Departments of two centers in Turkey. Girls treated with GnRH analogs
between March 2018 and 2022 were categorized into two groups: the pre-pandemic group
(2018-2020) and the pandemic group (2020-2022). Clinical, anthropometric, and hormonal
data were analyzed. Patients with organic lesions, genetic conditions, or medications
affecting puberty were excluded.
Inclusion Criteria (Who Can Participate?)
Girls: Tanner stage ≥2 before age 8 peak LH > on gnrh analog test, basal Lh >0,3
Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital
malformations, oncological diseases, neurosurgical or genetic disorders, or medications
affecting puberty were excluded from the study
the Pediatric Endocrinology Departments of Umraniye Training and Research Hospital
Istanbul 745044, Istanbul 745042, Turkey (Türkiye)
Not Provided